BRPI0411393A - vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor - Google Patents

vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor

Info

Publication number
BRPI0411393A
BRPI0411393A BRPI0411393-4A BRPI0411393A BRPI0411393A BR PI0411393 A BRPI0411393 A BR PI0411393A BR PI0411393 A BRPI0411393 A BR PI0411393A BR PI0411393 A BRPI0411393 A BR PI0411393A
Authority
BR
Brazil
Prior art keywords
sars
surface expression
expression vector
vector
antigen
Prior art date
Application number
BRPI0411393-4A
Other languages
English (en)
Inventor
Sung Moon-Hee
Chul Kim Joong
Chang Jung Min
Seung Hong Pyo
Jong Lee Su
Jae Choi Chul
Kim Kwang
Shunichi Kuroda
Ha Poo Ryong
Original Assignee
Bioleaders Corp
M D Lab
Bioleaders Japan Corp
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioleaders Corp, M D Lab, Bioleaders Japan Corp, Korea Res Inst Of Bioscience filed Critical Bioleaders Corp
Publication of BRPI0411393A publication Critical patent/BRPI0411393A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"VETOR DE EXPRESSãO DA SUPERFìCIE CELULAR DO ANTìGENO DO VìRUS SARS E MICROORGANISMOS TRANSFORMADOS PELO VETOR". A presente invenção refere-se a um vetor de expressão de superfície do antígeno coronavírus de SARS contendo um gene codificando um antígeno de SARS induzindo coronavírus e qualquer um ou dois ou mais genes pgsB, pgsC e pgsA codificando um complexo de sintase do ácido poli-gama-glutâmico, um microorganismo transformado pelo vetor de expressão de superfície, e uma vacina de SARS compreendendo o microorganismo. De acordo com a presente invenção, é possível produzir economicamente um vacina para prevenção e tratamento de SARS utilizando uma variedade recombinante expressando um antígeno de coronavírus de SARS em sua superfície.
BRPI0411393-4A 2003-06-04 2004-06-04 vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor BRPI0411393A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030035993 2003-06-04
PCT/KR2004/001341 WO2004108937A1 (en) 2003-06-04 2004-06-04 Cell surface expression vector of sars virus antigen and microorganisms transformed thereby

Publications (1)

Publication Number Publication Date
BRPI0411393A true BRPI0411393A (pt) 2006-08-01

Family

ID=36611852

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411393-4A BRPI0411393A (pt) 2003-06-04 2004-06-04 vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor

Country Status (10)

Country Link
US (1) US20060140971A1 (pt)
EP (1) EP1629104A4 (pt)
JP (1) JP2006526403A (pt)
KR (1) KR100469936B1 (pt)
CN (1) CN1798844A (pt)
AU (1) AU2004245859B2 (pt)
BR (1) BRPI0411393A (pt)
CA (1) CA2527346A1 (pt)
RU (1) RU2332457C2 (pt)
WO (1) WO2004108937A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050079162A (ko) * 2004-02-04 2005-08-09 주식회사 바이오리더스 파보바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
KR100517114B1 (ko) * 2005-02-25 2005-09-27 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 면역보강제 조성물
US20080206276A1 (en) 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
KR100872042B1 (ko) 2005-09-14 2008-12-05 주식회사 바이오리더스 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물
KR100782332B1 (ko) * 2006-01-23 2007-12-06 주식회사 바이오리더스 새우 흰 반점 바이러스 항원의 표면 발현벡터 및 이에 의해형질전환된 미생물
US20100248308A1 (en) * 2007-09-20 2010-09-30 Kazuhisa Sawada Recombinant Microorganism and a Method for Producing Poly-Gamma-Glutamic Acid
JP2014210747A (ja) 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
RU2739593C2 (ru) * 2015-03-05 2020-12-28 Петер Унд Траудль Энгельхорн-Штифтунг Цур Фёрдерунг Дер Лебенсвиссеншафтен Система презентации пептидов на клеточной поверхности
RU2639246C1 (ru) * 2016-12-21 2017-12-20 Федеральное государственное бюджетное учреждение "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт" - ГосНИИгенетика) Применение домена белка S-слоя из Lactobacillus brevis в качестве компонента системы для экспонирования слитых белков на поверхности клеток молочнокислых бактерий
EP3940077B1 (en) * 2018-10-10 2025-01-01 Bioleaders Corporation Surface expression vector using two kinds of promoters derived from lactobacillus casei for concurrently expressing two target proteins and method for expressing proteins on microbial surface by using same
US12180469B2 (en) * 2018-10-10 2024-12-31 Bioleaders Corporation Surface expression vector for constitutive high-expression using promoter of galactose mutarotase gene derived from Lactobacillus casei, and use thereof
IL294290A (en) * 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Transient temperature-based delivery of nucleic acids and proteins to cells and tissues
WO2021147025A1 (en) * 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
CN112877351A (zh) * 2020-04-14 2021-06-01 文利新 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN116507344A (zh) * 2020-06-26 2023-07-28 伊莱西奥治疗有限公司 用于诱导针对冠状病毒的免疫应答的组合物和方法
CA3183735A1 (en) * 2020-06-26 2021-12-30 Martin P. STEINBUCK Compositions and methods for inducing an immune response against coronavirus
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN112760336A (zh) * 2020-12-30 2021-05-07 广州辉园苑医药科技有限公司 一种抗原表位肽的表达系统和表面展示系统及它们的构建方法
JPWO2022163647A1 (pt) * 2021-01-26 2022-08-04
KR20220125776A (ko) 2021-03-07 2022-09-14 오영운 돼지갈비 포의 가공 및 분류방법
CA3228856A1 (en) * 2021-08-16 2023-02-23 Peter C. Demuth Compositions containing polynucleotide amphiphiles and methods of use thereof
WO2023044327A1 (en) * 2021-09-15 2023-03-23 Colorado State University Research Foundation Recombinant vaccine compositions
CN113755421B (zh) * 2021-09-28 2024-04-12 梦芊细胞因子有限公司 一种用于covid-19的口服性疫苗及抗体加强剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001017182A (ja) * 1999-07-09 2001-01-23 Nagase & Co Ltd ポリ−γ−グルタミン酸の製造方法
EP1421195B1 (en) * 2001-08-10 2006-10-18 Bioleaders Corporation SURFACE EXPRESSION VECTORS HAVING pgsBCA, THE GENE CODING POLY-GAMMA-GLUTAMATE SYNTHETASE, AND A METHOD FOR EXPRESSION OF TARGET PROTEIN AT THE SURFACE OF MICROORGANISM USING THE VECTOR
AU2003271215A1 (en) * 2002-10-17 2004-05-04 Bioleaders Corporation Vector for anti-hpv vaccine and transformed microorganism by the vector
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use

Also Published As

Publication number Publication date
JP2006526403A (ja) 2006-11-24
EP1629104A1 (en) 2006-03-01
EP1629104A4 (en) 2006-11-02
KR100469936B1 (ko) 2005-02-03
KR20040104936A (ko) 2004-12-13
RU2332457C2 (ru) 2008-08-27
WO2004108937A1 (en) 2004-12-16
AU2004245859A1 (en) 2004-12-16
CN1798844A (zh) 2006-07-05
AU2004245859B2 (en) 2007-02-08
US20060140971A1 (en) 2006-06-29
RU2005141528A (ru) 2006-06-27
CA2527346A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
BRPI0411393A (pt) vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor
MY140829A (en) Chimeric adenoviruses for use in cancer treatment
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
ES2527411T3 (es) Gen que confiere resistencia a Phytophthora infestans (tizón tardío) en solanáceas
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
AUPN477695A0 (en) Gene therapy
BR112021012240A2 (pt) Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich
NZ599590A (en) Factor involved in latent infection with herpesvirus, and use thereof
EP0756006A3 (en) Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
BR0113681A (pt) Polipeptìdeo tendo atividade da enzima lipoxigenase, polinucleotìdeo, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para produzir uma lipoxigenase, sonda de oligonucleotìdeo, método para obter um polipeptìdeo com atividade de lipoxigenase, composição de massa, métodos para preparar uma massa ou um produto assado produzido da massa, e para oxigenar um substrato, e, composição detergente
BR0314893A (pt) Vetor para vacina contra hpv e microrganismo transformado pelo vetor
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
BRPI0504945A8 (pt) Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
BR9902019A (pt) Moléculas de polinucleotìdios que codificam proteìnas de neospora.
BR9914892A (pt) Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor
WO2001072977A3 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
BRPI0407555A (pt) vetor inédito
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
BR9915703A (pt) Mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva
AR021450A1 (es) "molecula polinucleotidica que comprende una secuencia de nucleotidos de streptomices avermitil que dirige la relacion de avermectinas b2:b1, vector recombinante, celula huesped, procedimiento para obtener una cepa de s. avermitilis, celula de s. avermitilis que comprende dicha secuencia y procedimi
ATE453708T1 (de) Impfstoff gegen west nile virus
ATE556140T1 (de) Aav vektoren für die gentherapie von rheumatischer arthritis
CO5070698A1 (es) Gen de streptomyces avermitilis que dirige la relacion de avermectinas b2:b1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.